| Title |
Long-acting preparations of exenatide
|
|---|---|
| Published in |
Drug Design, Development and Therapy, September 2013
|
| DOI | 10.2147/dddt.s46970 |
| Pubmed ID | |
| Authors |
Yunpeng Cai, Liangming Wei, Liuqing Ma, Xiwen Huang, Anqi Tao, Zhenguo Liu, Weien Yuan |
| Abstract |
Exenatide has been widely used for the treatment of type 2 diabetes mellitus. However, its short plasma half-life of 2.4 hours has limited its clinical application. The exenatide products on the market, twice-daily Byetta™ and once-weekly Bydureon™ (both Amylin Pharmaceuticals, San Diego, CA, USA), are still not perfect. Many researchers have attempted to prolong the acting time of exenatide by preparing sustained-release dosage forms, modifying its structure, gene therapies, and other means. This review summarizes recent advances in long-acting exenatide preparations. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 85 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 1% |
| South Africa | 1 | 1% |
| Unknown | 83 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 15 | 18% |
| Researcher | 12 | 14% |
| Other | 10 | 12% |
| Student > Master | 10 | 12% |
| Student > Bachelor | 5 | 6% |
| Other | 13 | 15% |
| Unknown | 20 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 17 | 20% |
| Agricultural and Biological Sciences | 13 | 15% |
| Medicine and Dentistry | 11 | 13% |
| Biochemistry, Genetics and Molecular Biology | 5 | 6% |
| Materials Science | 4 | 5% |
| Other | 11 | 13% |
| Unknown | 24 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 September 2023.
All research outputs
#5,165,888
of 25,374,647 outputs
Outputs from Drug Design, Development and Therapy
#336
of 2,268 outputs
Outputs of similar age
#42,526
of 212,478 outputs
Outputs of similar age from Drug Design, Development and Therapy
#4
of 49 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 212,478 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.